CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Pliant Therapeutics, Inc. - PLRX CFD

13.94
0.87%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.09
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Pliant Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 13.84
Open* 13.97
1-Year Change* -28.25%
Day's Range* 13.85 - 14.55
52 wk Range 12.61-36.64
Average Volume (10 days) 482.21K
Average Volume (3 months) 12.34M
Market Cap 846.93M
P/E Ratio -100.00K
Shares Outstanding 59.90M
Revenue 3.55M
EPS -2.78
Dividend (Yield %) N/A
Beta 1.15
Next Earnings Date Mar 7, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Nov 29, 2023 13.84 -0.09 -0.65% 13.93 14.61 13.82
Nov 28, 2023 14.12 0.15 1.07% 13.97 14.21 13.73
Nov 27, 2023 14.14 0.07 0.50% 14.07 14.26 13.67
Nov 24, 2023 14.13 0.56 4.13% 13.57 14.42 13.57
Nov 22, 2023 13.91 -0.22 -1.56% 14.13 14.37 13.75
Nov 21, 2023 14.10 0.13 0.93% 13.97 14.37 13.71
Nov 20, 2023 14.33 0.20 1.42% 14.13 15.04 14.07
Nov 17, 2023 14.13 0.86 6.48% 13.27 14.14 13.27
Nov 16, 2023 13.46 0.07 0.52% 13.39 13.58 13.09
Nov 15, 2023 13.55 0.57 4.39% 12.98 14.12 12.96
Nov 14, 2023 13.13 -0.21 -1.57% 13.34 13.39 12.84
Nov 13, 2023 12.81 -0.57 -4.26% 13.38 13.41 12.55
Nov 10, 2023 13.78 -1.57 -10.23% 15.35 15.83 13.78
Nov 9, 2023 14.17 -0.64 -4.32% 14.81 15.11 14.11
Nov 8, 2023 14.98 -0.29 -1.90% 15.27 15.36 14.72
Nov 7, 2023 15.63 0.59 3.92% 15.04 16.04 15.04
Nov 6, 2023 15.42 -0.60 -3.75% 16.02 16.25 15.38
Nov 3, 2023 16.08 1.34 9.09% 14.74 16.33 14.74
Nov 2, 2023 15.01 0.11 0.74% 14.90 15.11 14.68
Nov 1, 2023 14.80 0.31 2.14% 14.49 15.09 14.48

Pliant Therapeutics, Inc. Events

Time (UTC) Country Event
Thursday, March 7, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 Pliant Therapeutics Inc Earnings Release
Q4 2023 Pliant Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 9.685 7.572 41.817 57.052 0
Total Operating Expense 136.885 105.107 83.462 58.283 30.915
Selling/General/Admin. Expenses, Total 39.949 27.558 17.269 10.93 6.5
Research & Development 96.936 77.549 66.193 47.353 24.415
Operating Income -127.2 -97.535 -41.645 -1.231 -30.915
Interest Income (Expense), Net Non-Operating 3.879 0.272 0.478 0.816 0.688
Other, Net -0.366 -0.216 -0.049
Net Income Before Taxes -123.321 -97.263 -41.533 -0.631 -30.276
Net Income After Taxes -123.321 -97.263 -41.533 -0.631 -30.276
Net Income Before Extra. Items -123.321 -97.263 -41.533 -0.631 -30.276
Net Income -123.321 -97.263 -41.533 -0.631 -30.276
Total Adjustments to Net Income 0 0 -6.225 -4.876
Income Available to Common Excl. Extra. Items -123.321 -97.263 -41.533 -6.856 -35.152
Income Available to Common Incl. Extra. Items -123.321 -97.263 -41.533 -6.856 -35.152
Diluted Net Income -123.321 -97.263 -41.533 -6.856 -35.152
Diluted Weighted Average Shares 42.0159 35.8464 21.3442 34.2014 34.2014
Diluted EPS Excluding Extraordinary Items -2.9351 -2.71333 -1.94586 -0.20046 -1.0278
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -2.9351 -2.71333 -1.94586 -0.20046 -1.0278
Revenue 9.685 7.572 41.817 57.052 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0.248 1.332 1.965 1.482 4.989
Revenue 0.248 1.332 1.965 1.482 4.989
Total Operating Expense 47.576 43.427 39.365 33.429 34.631
Selling/General/Admin. Expenses, Total 14.574 14.154 14.251 8.823 8.296
Research & Development 33.002 29.273 25.114 24.606 26.335
Operating Income -47.328 -42.095 -37.4 -31.947 -29.642
Interest Income (Expense), Net Non-Operating 6.136 4.547 2.34 1.332 0.096
Net Income Before Taxes -41.192 -37.548 -35.06 -30.615 -29.546
Net Income After Taxes -41.192 -37.548 -35.06 -30.615 -29.546
Net Income Before Extra. Items -41.192 -37.548 -35.06 -30.615 -29.546
Net Income -41.192 -37.548 -35.06 -30.615 -29.546
Income Available to Common Excl. Extra. Items -41.192 -37.548 -35.06 -30.615 -29.546
Income Available to Common Incl. Extra. Items -41.192 -37.548 -35.06 -30.615 -29.546
Diluted Net Income -41.192 -37.548 -35.06 -30.615 -29.546
Diluted Weighted Average Shares 59.1729 56.0576 48.8576 46.7991 36.1731
Diluted EPS Excluding Extraordinary Items -0.69613 -0.66981 -0.7176 -0.65418 -0.81679
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.69613 -0.66981 -0.7176 -0.65418 -0.81679
Total Adjustments to Net Income
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 340.311 209.441 290.754 111.9 61.733
Cash and Short Term Investments 331.187 200.596 276.894 102.773 60.949
Cash & Equivalents 33.685 51.665 50.882 85.807 60.949
Total Receivables, Net 2.066 2.081 9.362 7.385 0.5
Prepaid Expenses 6.885 6.764 4.498 1.742 0.284
Total Assets 350.613 221.215 295.526 119.064 66.529
Property/Plant/Equipment, Total - Net 9.908 10.936 4.321 4.079 4.26
Property/Plant/Equipment, Total - Gross 16.749 15.955 7.809 6.267 5.335
Accumulated Depreciation, Total -6.841 -5.019 -3.488 -2.188 -1.075
Other Long Term Assets, Total 0.394 0.838 0.451 3.085 0.536
Total Current Liabilities 23.913 16.831 11.599 8.172 5.084
Accounts Payable 1.58 2.971 2.023 1.25 2.576
Accrued Expenses 22.333 13.86 9.576 6.922 2.508
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 37.271 22.156 12.465 9.084 5.895
Total Long Term Debt 9.929 0 0 0 0
Other Liabilities, Total 3.429 5.325 0.866 0.912 0.811
Total Equity 313.342 199.059 283.061 109.98 60.634
Redeemable Preferred Stock 0 186.275 132.103
Common Stock 0.005 0.003 0.003 0.001 0.001
Additional Paid-In Capital 653.707 414.348 400.918 0 0
Retained Earnings (Accumulated Deficit) -338.412 -215.091 -117.828 -76.295 -71.47
Total Liabilities & Shareholders’ Equity 350.613 221.215 295.526 119.064 66.529
Total Common Shares Outstanding 48.9412 36.0833 35.5528 34.2014 34.2014
Short Term Investments 297.502 148.931 226.012 16.966 0
Accounts Receivable - Trade, Net 1.983 1.998 9.279 7.052 0
Unrealized Gain (Loss) -0.001 0
Preferred Stock - Non Redeemable, Net 0
Other Equity, Total -1.958 -0.201 -0.032
Other Current Assets, Total 0.173
Long Term Debt 9.929
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 534.335 565.701 588.227 340.311 365.965
Cash and Short Term Investments 523.612 555.159 577.314 331.187 360.241
Cash & Equivalents 57.679 54.951 102.527 33.685 44.617
Short Term Investments 465.933 500.208 474.787 297.502 315.624
Total Receivables, Net 2.122 4.022 4.757 2.066 1.565
Accounts Receivable - Trade, Net 0 1.58 3.297 1.983 1.482
Prepaid Expenses 7.933 6.291 5.738 7.058 4.159
Total Assets 540.464 574.891 597.881 350.613 377.181
Property/Plant/Equipment, Total - Net 5.737 8.518 9.01 9.908 10.819
Property/Plant/Equipment, Total - Gross 13.955 16.288 16.303 16.749 17.205
Accumulated Depreciation, Total -8.218 -7.77 -7.293 -6.841 -6.386
Other Long Term Assets, Total 0.392 0.672 0.644 0.394 0.397
Total Current Liabilities 27.395 29.52 23.153 23.913 26.161
Accounts Payable 3.36 2.31 1.419 1.58 3.206
Accrued Expenses 24.035 27.21 21.734 22.333 22.955
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 37.416 41.826 35.961 37.271 40.187
Total Long Term Debt 10.021 9.988 9.958 9.929 9.9
Other Liabilities, Total 0 2.318 2.85 3.429 4.126
Total Equity 503.048 533.065 561.92 313.342 336.994
Common Stock 0.006 0.006 0.006 0.005 0.005
Additional Paid-In Capital 963.588 952.452 939.205 653.707 642.795
Retained Earnings (Accumulated Deficit) -458.639 -417.152 -375.96 -338.412 -303.352
Other Equity, Total -1.907 -2.241 -1.331 -1.958 -2.454
Total Liabilities & Shareholders’ Equity 540.464 574.891 597.881 350.613 377.181
Total Common Shares Outstanding 59.891 59.2227 58.9789 48.9412 48.7498
Long Term Debt 10.021 9.988 9.958 9.929 9.9
Other Current Assets, Total 0.668 0.229 0.418
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -123.321 -97.263 -41.533 -0.631 -30.276
Cash From Operating Activities -94.631 -75.443 -37.271 -2.75 -28.328
Cash From Operating Activities 1.823 1.535 1.31 1.113 0.666
Non-Cash Items 22.65 13.368 4.161 1.829 0.228
Changes in Working Capital 4.217 6.917 -1.209 -5.061 1.054
Cash From Investing Activities -150.204 73.699 -210.866 -17.931 -2.323
Capital Expenditures -1.76 -1.953 -1.532 -0.964 -2.323
Cash From Financing Activities 226.854 2.527 213.212 45.539 87.349
Issuance (Retirement) of Stock, Net 217.561 2.984 213.212 48.121 87.349
Net Change in Cash -17.981 0.783 -34.925 24.858 56.698
Other Investing Cash Flow Items, Total -148.444 75.652 -209.334 -16.967 0
Financing Cash Flow Items -0.557 -0.457 0 -2.582 0
Cash Interest Paid 0.615
Issuance (Retirement) of Debt, Net 9.85
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -37.548 -123.321 -88.261 -57.646 -28.1
Cash From Operating Activities -30.276 -94.631 -63.392 -44.894 -20.498
Cash From Operating Activities 0.452 1.823 1.368 0.914 0.455
Non-Cash Items 9.948 22.65 12.739 8.061 4.047
Changes in Working Capital -3.128 4.217 10.762 3.777 3.1
Cash From Investing Activities -174.208 -150.204 -170.226 8.026 1.531
Capital Expenditures -0.163 -1.76 -1.594 -0.898 -0.644
Other Investing Cash Flow Items, Total -174.045 -148.444 -168.632 8.924 2.175
Cash From Financing Activities 273.326 226.854 226.57 10.273 -0.153
Financing Cash Flow Items -0.586 -0.557 -0.936 -0.225 -0.204
Issuance (Retirement) of Stock, Net 273.912 217.561 217.506 0.498 0.051
Net Change in Cash 68.842 -17.981 -7.048 -26.595 -19.12
Issuance (Retirement) of Debt, Net 0 9.85 10 10
Cash Interest Paid 0.282 0.615
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Fidelity Management & Research Company LLC Investment Advisor 7.0896 4242023 -289492 2023-06-30 LOW
Deep Track Capital LP Hedge Fund 6.7687 4050000 627943 2023-06-30 MED
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.9754 3575324 2319455 2023-06-30 LOW
Laurion Capital Management LP Hedge Fund 5.2789 3158570 3158570 2023-06-30 HIGH
Cowen Investment Management LLC Investment Advisor/Hedge Fund 5.2094 3117017 115182 2023-06-30 HIGH
T. Rowe Price Associates, Inc. Investment Advisor 4.8448 2898831 835917 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.6253 2767507 404136 2023-06-30 LOW
Redmile Group, LLC Investment Advisor/Hedge Fund 4.4759 2678099 -247549 2023-06-30 LOW
Third Rock Ventures, LLC Venture Capital 4.1315 2472027 -1500000 2023-06-30 MED
Novartis AG Corporation 3.5992 2153526 0 2022-08-08 LOW
First Light Asset Management, LLC Investment Advisor/Hedge Fund 3.0253 1810176 384822 2023-06-30 LOW
RA Capital Management, LP Hedge Fund 2.9448 1762000 0 2023-06-30 LOW
Casdin Capital, LLC Hedge Fund 2.8412 1700000 25000 2023-06-30 LOW
Polar Capital LLP Investment Advisor/Hedge Fund 2.7409 1640000 -143164 2023-06-30 LOW
Citadel Advisors LLC Hedge Fund 2.6956 1612907 498079 2023-06-30 LOW
Great Point Partners, LLC Hedge Fund 2.5908 1550184 338088 2023-06-30 HIGH
Franklin Advisers, Inc. Investment Advisor/Hedge Fund 2.4867 1487882 10623 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.0138 1204940 914839 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.652 988472 558253 2023-06-30 LOW
DWS Investment GmbH Investment Advisor/Hedge Fund 1.5963 955133 142933 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Pliant Therapeutics, Inc. Company profile

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. It focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-B). Its lead product candidate, PLN-74809, is an oral small-molecule, dual-selective inhibitor of avß6 and avB1. The Company’s second product candidate, PLN-1474, is a small-molecule, selective inhibitor of avB1 for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs. The first preclinical program is oncology program. Its second preclinical program is an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor being developed for treatment of muscular dystrophies, including duchenne muscular dystrophy.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Pliant Therapeutics Inc revenues decreased 82% to $7.6M. Net loss increased from $41.5M to $97.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 14% to $73.6M (expense), General and administrative - Balancing increase of 39% to $21M (expense).

Industry: Pharmaceuticals (NEC)

260 Littlefield Avenue
Suite 150
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

Income Statement

  • Annual
  • Quarterly

News

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023
GBP

UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

10:48, 21 November 2023

Gold Rises as Traders price-in Fed Rate Cuts

Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.

13:17, 20 November 2023

People also watch

Gold

2,035.47 Price
-0.400% 1D Chg, %
Long position overnight fee -0.0196%
Short position overnight fee 0.0114%
Overnight fee time 22:00 (UTC)
Spread 0.30

XRP/USD

0.61 Price
-0.620% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

BTC/USD

37,811.75 Price
-0.040% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

US100

15,859.10 Price
-0.840% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading